Ajjai Alva, MD
Medical Oncology · Overland Park, KSNPI 1497979678
Payments from drug & device makers
Across 498 payments — averaging $7361.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1.4M
- Merck$1.3M
- Astellas Pharma Global Development$359K
- Seagen Inc.$204K
- Bayer$87K
- Bristol Myers Squibb$85K
- plus $252K from 19 others
Across 1 payment — averaging $2813.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $1,383,803 |
| Merck | 349 | $1,295,759 |
| Astellas Pharma Global Development | 4 | $358,559 |
| Seagen Inc. | 44 | $204,346 |
| Bayer | 3 | $86,572 |
| Bristol Myers Squibb | 2 | $84,560 |
| Clovis Oncology, Inc. | 16 | $67,887 |
| E.r. Squibb & Sons, L.L.C. | 7 | $63,718 |
| Janssen Research & Development, LLC | 7 | $60,887 |
| F. Hoffmann-la Roche AG | 5 | $29,072 |
| Pfizer | 22 | $26,581 |
| Eisai Inc. | 3 | $3,661 |
| Sanofi | 2 | $287 |
| Foundation Medicine, Inc. | 1 | $81 |
| Ferring Pharmaceuticals Inc. | 2 | $72 |
| Johnson & Johnson | 2 | $46 |
| Verity Pharmaceuticals Inc. | 2 | $34 |
| Urogen Pharma, Inc. | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Endo USA, Inc. | 1 | $23 |
| Procept Biorobotics Corporation | 1 | $22 |
| Pharmaand GmbH | 1 | $22 |
| Tolmar, Inc. | 1 | $22 |
| Immunitybio, Inc. | 1 | $17 |
| Accord Healthcare, Inc. | 1 | $16 |
How this compares
$3,666,094 in reported general payments places this provider in the 85th percentile of 25 medical oncology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Overland Park
- Nisreen HaideriOverland Park$1.2M
- Muzaffar IqbalOverland Park$2K
- Weijing SunWestwood$5.1M
- Rahul ParikhWestwood$4.5M
- Anwaar SaeedWestwood$4.1M
- Joaquina BarandaWestwood$2.7M
- Anne OdeaWestwood$2.2M
- Benjamin GeorgeColby$1.1M
- Stephen WilliamsonWestwood$861K
- Elizabeth WulffWestwood$529K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.